OLMA
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Olema Pharmaceuticals, Inc. (OLMA) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D). The rating has held at C- for 7 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | C+ (2.5) | D+ (1.6) | D (1.5) | D+ (1.6) | C+ (2.6) | C- (2.0) |
| 2026-11-07 | C+ (2.5) | D+ (1.6) | D+ (1.5) | D+ (1.5) | C+ (2.7) | C- (2.0) |
| 2026-10-31 | C+ (2.5) | D+ (1.6) | D+ (1.5) | D+ (1.6) | C+ (2.7) | C- (2.0) |
| 2026-10-24 | C+ (2.5) | D+ (1.6) | D+ (1.5) | D+ (1.5) | C+ (2.6) | C- (1.9) |
| 2026-10-17 | C+ (2.5) | D+ (1.6) | D+ (1.5) | D (1.5) | C+ (2.6) | C- (1.9) |